Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Huya Bioscience has entered into a strategic partnership with the School of Chinese Materia Medica of the Beijing University of Chinese Medicine (BUCM).
Subscribe to our email newsletter
Huya said that the agreement with the School of Chinese Materia Medica of BUCM provides it with access to and first review of certain new therapeutic candidates owned or controlled by the school. In return, the school gains access to Huya’s expertise in preclinical and clinical development and its network of pharmaceutical partners.
Huya stated that the School of Chinese Materia Medica of BUCM is recognised for its research on traditional Chinese medicine (TCM). The company is into developing new therapeutics from TCM in areas of unmet medical needs. HBI-3000, Huya’s new anti-arrhythmic compound currently in development in both China and the US, was originally derived from a TCM.
Mireille Gingras, president and CEO of Huya, said: “The partnership between Huya and BUCM’s School of Chinese Materia Medica is expected to benefit patients. We look forward to collaborating with the school’s research staff to address the need for new pharmaceutical products.”
Renbing Shi, dean of the School of Chinese Materia Medica, Beijing University of Chinese Medicine, said: “We are pleased to partner with Huya’s team to share knowledge and engage in co-development activities that is expected to enhance our research programs.”